Girodmedical has raised US$2 million
Girodmedical SAS has raised US$2 million on a first round of financing via Audacia SAS.
Girodmedical offers medical equipment and medical supplies online. These include massage tables, accessories and furniture, diagnostic equipment and accessories, anatomy models and physiology and anatomy books, medical uniforms and hygiene disinfection and protection products and disposable paper supplies. The company also provides surgical equipment, physiotherapy and rehabilitation products and fitness and sporting goods, comfort and well-being products (such as dental hygiene and aesthetic care) and assisted living products (such as big button phones and incontinence products). Girodmedical was incorporated in 2004 and is based in Nantes, France.
Oaklins’ team in France advised the shareholders of Girodmedical SAS on this transaction.
Talk to the deal team
Related deals
Lindenhofgruppe has sold its majority stake in LabPoint to Affidea Switzerland
LabPoint Medical Laboratories AG has been acquired by Affidea Switzerland AG. Through the transaction, Lindenhofgruppe AG gains a strong strategic partner to support the further development of LabPoint and will remain a shareholder with a reduced stake, continuing as a key customer of the company. It lays the foundation for LabPoint’s sustainable development under a new anchor shareholder, with the aim of further strengthening and selectively expanding its position in laboratory diagnostics.
Learn moreEuroHospital Varna has been acquired by Intermedica Group
EuroHospital Varna has been acquired by Intermedica Group, allowing the business to continue to grow and deliver high-quality healthcare services to its patients. Through the transaction, Intermedica Group expands its healthcare presence and intends to build a new model of integrated personalized care focused on preventive, holistic and digital medicine.
Learn moreOlyos Group has acquired a controlling stake in NewScience
Olyos Group has acquired a controlling stake in NewScience from its founders through a transaction structured in two stages, with the strategic objective of ultimately acquiring 100% of the company. The transaction forms part of NewScience’s international growth strategy and a gradual cash-out process for the founder, who intends to complete a full exit. Olyos intends to retain the management team through a put and call option mechanism and an earn-out linked to NewScience’s 2025 EBITDA.
Learn more